
Sign up to save your podcasts
Or


The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:
By JAMA Network4.6
162162 ratings
The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:

38,538 Listeners

43,506 Listeners

27,116 Listeners

136 Listeners

328 Listeners

546 Listeners

707 Listeners

500 Listeners

6,446 Listeners

298 Listeners

264 Listeners

3,384 Listeners

20 Listeners

14 Listeners

8 Listeners

7 Listeners

19 Listeners

29 Listeners

90 Listeners

517 Listeners

362 Listeners

19 Listeners

377 Listeners